RU2506267C2 - Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение - Google Patents

Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение Download PDF

Info

Publication number
RU2506267C2
RU2506267C2 RU2010143319/04A RU2010143319A RU2506267C2 RU 2506267 C2 RU2506267 C2 RU 2506267C2 RU 2010143319/04 A RU2010143319/04 A RU 2010143319/04A RU 2010143319 A RU2010143319 A RU 2010143319A RU 2506267 C2 RU2506267 C2 RU 2506267C2
Authority
RU
Russia
Prior art keywords
thieno
dihydrobenzo
oxepine
methyl
triazol
Prior art date
Application number
RU2010143319/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010143319A (ru
Inventor
Бин-Янь ЧЖУ
Пол ГОЛДСМИТ
Трэйси БЭЙЛИСС
Эдриан ФОЛКС
Нил ПЭГГ
Стивен ДО
Ричард ГОЛДСМИТ
Тим ХЕФФРОН
Александр КОЛЕСНИКОВ
Стивен СТАБЕН
Алан Г. Оливеро
Майкл СЮ
Дэниель П. САЗЕРЛИН
Original Assignee
Дженентек, Инк.
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк., Ф. Хоффманн-Ля Рош Аг filed Critical Дженентек, Инк.
Publication of RU2010143319A publication Critical patent/RU2010143319A/ru
Application granted granted Critical
Publication of RU2506267C2 publication Critical patent/RU2506267C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2010143319/04A 2008-03-31 2009-03-30 Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение RU2506267C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4082708P 2008-03-31 2008-03-31
US61/040,827 2008-03-31
US10222008P 2008-10-02 2008-10-02
US61/102,220 2008-10-02
PCT/US2009/038795 WO2009123971A1 (en) 2008-03-31 2009-03-30 Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use

Publications (2)

Publication Number Publication Date
RU2010143319A RU2010143319A (ru) 2012-05-10
RU2506267C2 true RU2506267C2 (ru) 2014-02-10

Family

ID=40790991

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010143319/04A RU2506267C2 (ru) 2008-03-31 2009-03-30 Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение

Country Status (21)

Country Link
US (4) US7928248B2 (enExample)
EP (1) EP2276767B1 (enExample)
JP (1) JP5511786B2 (enExample)
KR (1) KR101626996B1 (enExample)
CN (1) CN102333779B (enExample)
AR (1) AR071112A1 (enExample)
AU (1) AU2009231885B2 (enExample)
BR (1) BRPI0910346A2 (enExample)
CA (1) CA2719032C (enExample)
CL (1) CL2009000780A1 (enExample)
DK (1) DK2276767T3 (enExample)
ES (1) ES2480994T3 (enExample)
IL (1) IL208359A (enExample)
MX (1) MX2010010659A (enExample)
PE (1) PE20091720A1 (enExample)
PL (1) PL2276767T3 (enExample)
RU (1) RU2506267C2 (enExample)
SI (1) SI2276767T1 (enExample)
TW (1) TWI443102B (enExample)
WO (1) WO2009123971A1 (enExample)
ZA (1) ZA201007218B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2721120C2 (ru) * 2015-03-30 2020-05-15 Джубилант Байосис Лимитед Новые гетероциклические соединения как ингибиторы brd4

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
WO2009123971A1 (en) 2008-03-31 2009-10-08 Genentech, Inc. Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
EA201200087A1 (ru) * 2009-07-02 2012-07-30 Новартис Аг 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
RU2600927C2 (ru) 2009-09-28 2016-10-27 Ф.Хоффманн-Ля Рош Аг Бензоксазепиновые ингибиторы pi3k и способы применения
PE20140918A1 (es) * 2009-09-28 2014-08-06 Hoffmann La Roche Compuestos de benzoxepina inhibidores de la pi3k
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EP2493866A1 (en) * 2009-10-29 2012-09-05 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
US9073940B2 (en) 2009-11-13 2015-07-07 Merck Serono Sa Tricyclic pyrazol amine derivatives
WO2011063126A1 (en) * 2009-11-18 2011-05-26 Satoshi Ohtake Highly dispersible powders, compositions and methods for preparation
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
UY33554A (es) 2010-08-11 2012-02-29 Millennium Pharm Inc Heteroarilos y usos de los mismos
BR112013009166A2 (pt) * 2010-10-13 2016-07-26 Millennium Pharm Inc heteroarilas e uso das mesmas.
RU2013143747A (ru) * 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
KR101992311B1 (ko) 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
EP2714675B1 (en) 2011-05-27 2019-01-02 Lexicon Pharmaceuticals, Inc. 4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use
BR112014019209A2 (pt) 2012-02-17 2017-07-04 Hoffmann La Roche compostos tricíclicos e métodos de uso para os mesmos
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112014028881A2 (pt) 2012-05-23 2017-06-27 Hoffmann La Roche populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
KR101988079B1 (ko) 2012-07-04 2019-06-11 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
WO2014140073A1 (en) 2013-03-13 2014-09-18 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6454419B2 (ja) 2014-12-11 2019-01-16 ナトコ ファーマ リミテッド 抗癌剤としての７−（モルホリニル）−２−（Ｎ−ピペラジニル）メチルチエノ［２，３−ｃ］ピリジン誘導体
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20190403A1 (es) 2016-07-29 2019-03-13 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata
JP7029445B2 (ja) 2016-09-02 2022-03-03 ブリストル－マイヤーズ スクイブ カンパニー 置換された三環式ヘテロ環化合物
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
JP2020527593A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． １，８−ナフチリジノン化合物およびその使用
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
CN107805255B (zh) * 2017-09-22 2020-06-16 中国药科大学 呋喃[3，2-b]吡啶-2(1H)-酮类化合物、制备方法和医药用途
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
CN110467629B (zh) * 2018-05-09 2022-04-08 上海迪诺医药科技有限公司 苯醌衍生物、其药物组合物及应用
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
CN113939291A (zh) 2019-01-18 2022-01-14 诺维逊生物股份有限公司 1,8-萘啶酮化合物及其用途
CN114156414B (zh) * 2021-11-30 2024-05-31 合肥工业大学 一种高效稳定CsPbI3无机钙钛矿电池的制备方法
CN117209457B (zh) * 2022-06-09 2025-08-15 四川师范大学 一种α-手性脒化合物的合成
CN115403591A (zh) * 2022-10-08 2022-11-29 河南师范大学 一种合成萘并噻吩并奥塞平并异喹啉酮类化合物的方法
WO2025082467A1 (zh) * 2023-10-19 2025-04-24 成都先导药物开发股份有限公司 一种免疫调节剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2001104480A (ru) * 1998-07-17 2003-02-10 Авентис Фарма Дойчланд Гмбх Полициклические тиазолидин-2-илиденовые амины, способ их получения и их применение в качестве лекарственных средств
EP1403256A1 (en) * 2001-06-05 2004-03-31 Fujisawa Pharmaceutical Co., Ltd. Fused imidazole derivative
WO2006040279A1 (de) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh Pi3-kinasen
RU2281947C1 (ru) * 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
WO2008019139A2 (en) * 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
KR0126300B1 (ko) 1992-12-28 1997-12-26 나이토 하루오 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체
AU1272597A (en) 1995-11-17 1997-06-11 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
DE19831878C2 (de) * 1998-07-17 2001-05-17 Aventis Pharma Gmbh Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
US20040082602A1 (en) 2002-07-19 2004-04-29 Hagen Timothy J. Substituted thiophene carboxamide compounds for the treatment of inflammation
MXPA05008400A (es) 2003-02-07 2005-10-05 Warner Lambert Co Derivados de oxazolidinona n-sustituidos por un anillo triciclico, para su uso como agentes antibacterianos.
CN101039667A (zh) * 2004-10-15 2007-09-19 辉瑞大药厂 双相性精神障碍和相关症状的治疗
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
WO2009123971A1 (en) 2008-03-31 2009-10-08 Genentech, Inc. Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2001104480A (ru) * 1998-07-17 2003-02-10 Авентис Фарма Дойчланд Гмбх Полициклические тиазолидин-2-илиденовые амины, способ их получения и их применение в качестве лекарственных средств
EP1403256A1 (en) * 2001-06-05 2004-03-31 Fujisawa Pharmaceutical Co., Ltd. Fused imidazole derivative
WO2006040279A1 (de) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh Pi3-kinasen
RU2281947C1 (ru) * 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
WO2008019139A2 (en) * 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2721120C2 (ru) * 2015-03-30 2020-05-15 Джубилант Байосис Лимитед Новые гетероциклические соединения как ингибиторы brd4
US10689390B2 (en) 2015-03-30 2020-06-23 Jubilant Biosys Limited Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer
US11319326B2 (en) 2015-03-30 2022-05-03 Jubilant Biosys Limited Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer

Also Published As

Publication number Publication date
US20140336154A1 (en) 2014-11-13
JP5511786B2 (ja) 2014-06-04
CN102333779B (zh) 2015-12-09
US20130123263A1 (en) 2013-05-16
KR20100137551A (ko) 2010-12-30
ZA201007218B (en) 2012-06-27
AU2009231885A1 (en) 2009-10-08
PE20091720A1 (es) 2009-11-26
IL208359A0 (en) 2010-12-30
US7928248B2 (en) 2011-04-19
JP2011517457A (ja) 2011-06-09
AU2009231885B2 (en) 2014-04-03
CA2719032C (en) 2016-11-08
HK1147741A1 (en) 2011-08-19
US8846762B2 (en) 2014-09-30
EP2276767B1 (en) 2014-05-07
US9309265B2 (en) 2016-04-12
SI2276767T1 (sl) 2014-08-29
KR101626996B1 (ko) 2016-06-02
RU2010143319A (ru) 2012-05-10
TWI443102B (zh) 2014-07-01
DK2276767T3 (da) 2014-07-14
US20110130363A1 (en) 2011-06-02
TW200944531A (en) 2009-11-01
US20090247567A1 (en) 2009-10-01
CL2009000780A1 (es) 2010-01-15
IL208359A (en) 2016-07-31
ES2480994T3 (es) 2014-07-29
US8399690B2 (en) 2013-03-19
AR071112A1 (es) 2010-05-26
PL2276767T3 (pl) 2014-09-30
CN102333779A (zh) 2012-01-25
MX2010010659A (es) 2010-10-26
BRPI0910346A2 (pt) 2015-10-06
CA2719032A1 (en) 2009-10-08
EP2276767A1 (en) 2011-01-26
WO2009123971A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
RU2506267C2 (ru) Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
JP2011517457A5 (enExample)
AU2017260125B2 (en) Aromatic sulfonamide derivatives
RU2326881C9 (ru) Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k)
KR101784029B1 (ko) 비스아릴-결합된 아릴트리아졸론 및 그의 용도
RU2006130683A (ru) Производные 3-замещенного 1, 5-дифенилпиразола, полезные в качестве св1 модуляторов
CN116547279A (zh) 杂环glp-1激动剂
EA010132B1 (ru) Производные триазола в качестве антагонистов вазопрессина
JP2007523182A5 (enExample)
US7151182B2 (en) Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives
JP2008526723A5 (enExample)
RU2006127575A (ru) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2022550297A (ja) Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のヘテロ多環式モジュレーター
CA2388320A1 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
AU2003278600A1 (en) Agent for preventing or treating neuropathy
RU2016141646A (ru) Ингибиторы trka киназы, основанные на них композиции и способы
ES2557478T3 (es) Compuestos de pirazol y triazol como inhibidores de KSP
EA029718B1 (ru) Бифтордиоксалан-аминобензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс
RU2332996C2 (ru) Производные гидразонпиразола и их применение в качестве лекарственного средства
JP2020522490A (ja) 置換窒素含有化合物
JP2020504706A (ja) 置換窒素含有化合物
RU2006135482A (ru) Терапевтические агенты
RU2008108179A (ru) Производные пиразола в качестве терапевтических агентов
CA2878564A1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
RU2025106654A (ru) Гетероциклические соединения в качестве ингибиторов моноацилглицеринлипазы (magl)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190331